Comparative Efficacy of Metabolic/Bariatric Surgery Versus <scp>GLP</scp> ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials
Both MBS and GLP-1 RAs provide substantial metabolic benefits. MBS remains superior, but tirzepatide is a promising nonsurgical option supporting personalized obesity care.
Authors
- Víctor Valentí (ORCID: https://orcid.org/0000-0002-7074-2849)
- Fernando Rotellar (ORCID: https://orcid.org/0000-0002-6557-0712)
- Sanjay Purkayastha (ORCID: https://orcid.org/0000-0003-0187-8328)
- Manuel F. Landecho (ORCID: https://orcid.org/0000-0003-3234-8805)
- Nuria Blanco (ORCID: https://orcid.org/0009-0009-1495-2321)
- Patricia Ortega (ORCID: https://orcid.org/0009-0005-1840-2176)
- Lucas Sabatella (ORCID: https://orcid.org/0009-0003-1981-4194)
- Adriana Uriz Pagola
- Ahmed R. Ahmed (ORCID: https://orcid.org/0000-0002-8349-4688)
- Carlota Tuero Ojanguren
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Clinica Universidad de Navarra (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Obesity
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/oby.70100
- Citations
- 4
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 8.03